Abstract
Incidence of thyroid cancer (TC) has increased over the last decade, in most parts of the world, possibly because of increased ionizing radiations. We therefore analyzed records of patients with TC who were treated at our hospital (Prof. Dr. Ion Chiricuta, Institute of Oncology Cluj-Napoca, Romania) since the nuclear accident at Chernobyl in 1986. We performed a comparative analysis of the database for 10, 20 and 25 years after the Chernobyl accident. Changes in histological profiles and tumor sizes imply that, in addition to nuclear fallout, highly sensitive thyroid diagnostic procedures are responsible for this increase in reported incidence, which appears to be driven by improved discovery of small (< 1 cm) preclinical tumors. This invites a real public health question.
Keywords: Thyroid cancer, incidence, epidemiology.
Current Radiopharmaceuticals
Title:Thyroid Cancer Incidence 25 Years After Chernobyl, in a Romanian Cancer Center: Is it a Public Health Problem?
Volume: 6 Issue: 4
Author(s): Doina Piciu
Affiliation:
Keywords: Thyroid cancer, incidence, epidemiology.
Abstract: Incidence of thyroid cancer (TC) has increased over the last decade, in most parts of the world, possibly because of increased ionizing radiations. We therefore analyzed records of patients with TC who were treated at our hospital (Prof. Dr. Ion Chiricuta, Institute of Oncology Cluj-Napoca, Romania) since the nuclear accident at Chernobyl in 1986. We performed a comparative analysis of the database for 10, 20 and 25 years after the Chernobyl accident. Changes in histological profiles and tumor sizes imply that, in addition to nuclear fallout, highly sensitive thyroid diagnostic procedures are responsible for this increase in reported incidence, which appears to be driven by improved discovery of small (< 1 cm) preclinical tumors. This invites a real public health question.
Export Options
About this article
Cite this article as:
Piciu Doina, Thyroid Cancer Incidence 25 Years After Chernobyl, in a Romanian Cancer Center: Is it a Public Health Problem?, Current Radiopharmaceuticals 2013; 6 (4) . https://dx.doi.org/10.2174/1874471006666140109114218
DOI https://dx.doi.org/10.2174/1874471006666140109114218 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Development of WT1 Peptide Cancer Vaccine Against Hematopoietic Malignancies and Solid Cancers
Current Medicinal Chemistry Novel Drugs Targeting the c-Ring of the F<sub>1</sub>F<sub>O</sub>-ATP Synthase
Mini-Reviews in Medicinal Chemistry PET with Non-Standard Nuclides
Current Topics in Medicinal Chemistry The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Research and Development of B-Raf Inhibitors
Current Medicinal Chemistry One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Application of Serial Analysis of Gene Expression in Cancer Research
Current Pharmaceutical Biotechnology Threat Posed by Persistent Organochlorine Pesticides and their Mobility in the Environment
Current Organic Chemistry Recent Clinical Aspects of Hyperprolactinemia Induced by Antipsychotics
Reviews on Recent Clinical Trials Organoselenium Compounds as Potential Neuroprotective Therapeutic Agents
Current Organic Chemistry Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications
Current Medicinal Chemistry Two Novel GPER Agonists Induce Gene Expression Changes and Growth Effects in Cancer Cells
Current Cancer Drug Targets Significance of Metallothionein Expression in Liver Disease
Current Pharmaceutical Biotechnology Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design New Insights on the Xenobiotic-Sensing Nuclear Receptors in Liver Diseases – CAR and PXR-
Current Drug Metabolism Catalytic Activity of Certain Antibodies as a Potential Tool for Drug Synthesis and for Directed Prodrug Therapies
Current Medicinal Chemistry